Linker technology in antibody-drug conjugates for cancer treatment

Shino Manabe

doi:10.2745/dds.28.406

Linker technology in antibody-drug conjugates for cancer treatment

Shino Manabe

PHA - Graduate School of Pharmaceutical Sciences (department affiliation only)

Research output: Contribution to journal › Article › peer-review

Abstract

Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.

Original language	English
Pages (from-to)	406-411
Number of pages	6
Journal	Drug Delivery System
Volume	28
Issue number	5
DOIs	https://doi.org/10.2745/dds.28.406
Publication status	Published - 2013

Keywords

Antibody-drug conjugate
Diketopiperazine
Linker
Spacer
Specifier

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2745/dds.28.406

Cite this

@article{ae64eea3f0674b5dad8b26b0e65767be,

title = "Linker technology in antibody-drug conjugates for cancer treatment",

abstract = "Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.",

keywords = "Antibody-drug conjugate, Diketopiperazine, Linker, Spacer, Specifier",

author = "Shino Manabe",

year = "2013",

doi = "10.2745/dds.28.406",

language = "English",

volume = "28",

pages = "406--411",

journal = "Drug Delivery System",

issn = "0913-5006",

publisher = "Japan Society of Drug Delivery System",

number = "5",

}

TY - JOUR

T1 - Linker technology in antibody-drug conjugates for cancer treatment

AU - Manabe, Shino

PY - 2013

Y1 - 2013

N2 - Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.

AB - Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.

KW - Antibody-drug conjugate

KW - Diketopiperazine

KW - Linker

KW - Spacer

KW - Specifier

UR - http://www.scopus.com/inward/record.url?scp=84940331523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940331523&partnerID=8YFLogxK

U2 - 10.2745/dds.28.406

DO - 10.2745/dds.28.406

M3 - Article

AN - SCOPUS:84940331523

SN - 0913-5006

VL - 28

SP - 406

EP - 411

JO - Drug Delivery System

JF - Drug Delivery System

IS - 5

ER -

Linker technology in antibody-drug conjugates for cancer treatment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this